I agree with you lrdpdx77,
Im also invested in other biotechs and the trend, unfortunately, at present in the markets is that positive read outs are no longer a green light for whales to jump in. Heck if anything its a green light to short the biotech stock after positive TLD.
Im afraid that the days for huge gains after positive TLD are for now over. Im convinced that the DCVAX L publication we are waiting for will show that DCVAX L will be the new SOC for true GBM. What I am however not so convinced about anymore is if that will set the SP to a level that most investors want it to jump to. The market yells at listed companies: SHOW ME THE MONEY. DD showed some sort of survey on Twitter of ¾ of people thinking NWBO SP will be above $20 at the end of Q1 after publication, I hope it will be so but Im afraid many will be disappointed if they have this as a price target.
We need uplisting, revenue and approval for a MC of > $ 20 billion.
Market Data 
Markets 
AI
